Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

The US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene ...

Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new ...

Flagship Pioneering -founded Valo Health has announced the appointment of Dr Brian Alexander as its new CEO. Additionally, ...

In Shanghai, more than 300 industry leaders, experts, and partners met to discuss the latest trends in the data centre ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...